Helse Fonna HF

The medical center is at the forefront of research into Dementia with Lewy Bodies, focusing on innovative therapeutic approaches to improve cognitive, neuropsychiatric, and functional outcomes. The center's work in this area is pivotal in enhancing the quality of life for patients through targeted interventions.

• Ambroxol efficacy in early-stage patients

By exploring the potential of Ambroxol, the center aims to provide new hope for those affected by this challenging condition.

Specializing in Small-cell Lung Cancer, the center is dedicated to advancing treatment protocols that integrate thoracic radiotherapy with immunotherapy and chemotherapy. This approach seeks to improve survival rates and offer a comprehensive treatment strategy for patients with extensive-stage disease.

• Concurrent thoracic radiotherapy and immunotherapy

The center's research is instrumental in redefining therapeutic standards and enhancing patient outcomes.

In the realm of Multiple Sclerosis, the center is pioneering studies on the safety and efficacy of novel add-on therapies. By investigating the integration of TAF with existing treatments, the center aims to offer improved management options for this chronic condition.

• TAF as an add-on therapy

This research is crucial in expanding therapeutic possibilities and improving patient care.

The center is committed to combating Alzheimer's Disease through innovative clinical trials. By evaluating the efficacy of Fasudil in preventing memory loss, the center is contributing to the development of new treatment avenues for early-stage patients.

• Fasudil for memory preservation

This research is vital in the quest to mitigate the impact of Alzheimer's on individuals and families.

Focusing on KRAS G12C-mutated Non-small Cell Lung Cancer, the center is evaluating the effectiveness of sotorasib in reducing tumor size. This research is pivotal in offering targeted treatment options for patients with specific genetic mutations.

• Sotorasib efficacy in mutation-specific cases

The center's work is essential in advancing personalized medicine and improving patient outcomes.

In the field of Immune Thrombocytopenia, the center is conducting comparative studies on second-line therapeutic approaches. By evaluating the efficacy of avatrombopag versus rituximab, the center aims to optimize treatment strategies for patients unresponsive to initial therapies.

• Comparative efficacy of avatrombopag and rituximab

This research is crucial in refining treatment protocols and enhancing patient care.

The center is a leader in implementing Precision Medicine for cancer care. By assessing the anti-tumor activity of targeted drugs, the center is facilitating patient access to effective treatments based on genomic and protein expression variants.

• Targeted anti-cancer drug efficacy

This research is instrumental in personalizing cancer treatment and improving therapeutic outcomes.

Specializing in Primary Adrenal Insufficiency, the center is evaluating the impact of different treatment regimens on health-related quality of life. By comparing Plenadren with conventional cortisone, the center aims to enhance patient well-being and treatment satisfaction.

• Quality of life assessment in treatment regimens

This research is vital in optimizing therapeutic approaches and improving patient quality of life.

The center is advancing the field of Breast Cancer research by identifying molecular markers that predict therapy response and survival outcomes. This work is crucial in tailoring treatments to individual patient profiles and improving prognostic accuracy.

• Molecular markers for therapy response

The center's research is pivotal in enhancing personalized treatment strategies and patient survival rates.